lifestyle.thedailyhaze.com

Author: Celcuity Inc.

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 25, 2026
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

March 18, 2026
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

March 18, 2026
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

March 9, 2026
Celcuity To Participate in Upcoming Investor Conferences

February 25, 2026
Celcuity Appoints Charles Romp to its Board of Directors

February 13, 2026
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

February 11, 2026
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

January 20, 2026